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Background: To assess the full root modification of the Ross procedure, we
examined operative and long-term results. Methods: We retrospectively
reviewed 145 patients (118 men and 27 women) operated on from March
1987 through April 1997. Ages ranged from 17 to 68 years. Primary
diagnosis was aortic stenosis in 43 patients (29.6%) and aortic regurgita-
tion in 62 patients (42.8%). There was mixed disease (stenosis and
regurgitation) in 40 patients (29.6%) of whom the vast majority had
predominant stenosis. Results: Early death was 7 of 145 patients (4.8%).
Twelve patients had 14 significant complications (8.5%). There were four
late deaths. Overall patient survival is 90.5% 6 3.1% at 5 years and 84.5%
6 14.1% at 7 years. Endocarditis occurred in three patients—two on the
autograft and one on the pulmonary homograft. Three patients had
cerebrovascular accidents. In 5 of 132 patients (3.8%) reoperations were
required on the autograft. Freedom from autograft reoperation was 93.9%
6 3.1% at 5 years and 88.6% 6 6.4% at 7 years. Echocardiographic
follow-up reveals more than mild aortic regurgitation in only nine patients,
including the five patients in whom reoperations were required. Seven of 11
patients with active endocarditis at the time of the operation had adverse
outcomes. Conclusions: Ten years’ experience with the modified Ross
procedure has shown excellent results with regard to short- and long-term
morbidity and death. It is the procedure of choice for young patients who
need aortic valve replacement but should be used with caution in the setting
of active endocarditis. (J Thorac Cardiovasc Surg 1998;115:1091-100)
In March 1967, Donald Ross
1 reported the first
pulmonary autograft replacement of the aortic
valve. His remarkable work clearly established the
procedure as an extremely important option for
patients with aortic valve disease. He found, how-
ever, that reoperation was ultimately necessary in 38
of 314 patients (12%) because of either endocarditis
or “technical incompetence” of the autograft valve.2
In efforts to improve the competency rate, Ross
modified his original freehand subcoronary tech-
nique to a “cylinder” technique in 1976 but still met
with a significant failure rate. On the basis of Ross’s
pioneering work with aortic homografts and his
observation that when used as a full root replace-
ment, the aortic homograft valve was “invariably
competent,”3 one of us (P.S.) postulated that the
same might be true for the pulmonary autograft.
The Ross procedure was thus modified to a full root
replacement 10 years ago to decrease the need for
reoperation. The technique has been previously
described.4-6 We have retrospectively reviewed the
outcome of 145 consecutive patients who underwent
the modified Ross procedure to define the results of
autograft root replacement and to provide as much
long-term follow-up as possible, focusing on the
incidence of significant autograft regurgitation and
need for reoperation.
Patients and methods
Patient population. From March 1987 through April
1997, 145 patients underwent aortic valve and root re-
placement with the pulmonary autograft (modified Ross
procedure) with a single (P.S.) responsible surgeon. There
were 118 men and 27 women. Age ranged from 17 to 68
years, with a mean of 43.1 years. The primary diagnosis
was aortic stenosis (AS) in 43 patients (29.6%) and aortic
regurgitation (AR) in 62 patients (42.8%). There was
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combined disease (AS/AR) in 40 patients (29.6%) of
which most had predominant AS (36 of 40 patients).
Table I shows the 18 previous cardiac operations done on
17 patients. There were 21 patients (14.5%) with an
endocarditis history—11 patients with active endocarditis
and 10 with healed endocarditis. Ten of the 11 active cases
and eight of the 10 healed cases involved native valves
(85.7%); only three cases involved prosthetic valves. Con-
comitant procedures were performed in 36 patients
(24.8%). There were 14 mitral procedures and 12 coro-
nary bypass procedures ranging from one to five grafts
(mean 2.2 grafts). Other procedures included subaortic
resections (n 5 3) and ascending aneurysm repairs (n 5
3), as shown in Table II.
Technique. All patients underwent the operation with
standard techniques of cardiopulmonary bypass with
cold cardioplegia (primarily blood and mostly retro-
grade) with moderate systemic hypothermia (30° to
32° C). Initial size estimates in recent experience have
been obtained with intraoperative transesophageal
echocardiography. The aortic anulus is estimated by
measuring from the interventricular septum to the
hinge point of the anterior mitral leaflet in the long axis,
and the pulmonary anulus is measured in the short axis.
The aortic dimension thus obtained is fairly accurate,
but difficulties imaging the proximal pulmonary trunk
make this less reliable.
Before the pulmonary trunk is harvested, the aortic
valve is excised and root measurements are made at the
level of the anulus with standard circular or cylindrical
sizers typically used for mechanical valve operations. The
pulmonary artery is divided just proximal to the bifurca-
tion leaving the anterior wall longer than the posterior.
The adventitia is preserved intact as much as possible; a 4
to 5 mm muscle cuff is kept on the proximal end, and the
first septal perforator is protected posteriorly. The excised
autograft is supported gently on the proximal end with a
forceps at each commissure, and the same cylindrical
sizers are used to measure the inside diameter without any
stretching of the anulus.
If the aortic root is more than 2 mm smaller than the
pulmonary (a rare situation), dividing the commissure
between the left and the noncoronary sinuses can enlarge
the root. On one occasion, annular hypoplasia and sub-
aortic stenosis required enlarging the root by a modified
Konno technique with extensive septal muscle excision,
seating the autograft down in the widened outflow tract.
Usually, in AS, the pulmonary anulus is just slightly larger
than the aortic anulus and fits nicely without tailoring. In
cases of primary regurgitation, the aortic anulus may be
considerably dilated; this must be addressed. The commis-
sures can be plicated down on either side of the noncoro-
nary sinus to reduce the anulus 4 to 5 mm, but a
discrepancy of over 10 mm is considered a contraindica-
tion to the procedure. With or without the plication, the
regurgitant anulus should be supported with a strip of
Teflon felt (5 to 7 mm wide), which is measured to length
around a sizer one size larger than the internal diameter
of the autograft. This strip is incorporated in the proximal
suture line of continuous 4-0 polypropylene placed at the
level of the anulus.
The aorta was transected completely in all but one case,
and the coronary arteries were mobilized with buttons of
aortic wall. (In that one case the left main was kept as a
“wagon tongue” on the distal aorta by carrying the line of
aortic transection down into the sinus below the ostium.)
The coronary buttons were then reimplanted with contin-
uous 6-0 polypropylene. The distal autograft-aortic suture
line was constructed with continuous 4-0 polypropylene. If
the distal aorta was dilated, it was either gathered and
supported with another felt strip and/or reduced with a
lateral wedge aortorrhaphy to appropriate size. Finally,
the right ventricular outflow tract (RVOT) was recon-
structed. All but four of these were done with cryopre-
served pulmonary homograft conduits.
Concomitant procedures were done first to ensure that
mitral valves, for example, could be repaired before
proceeding with the autograft harvest. Coronary artery
bypass grafting was done with the left internal thoracic
artery and recently, the radial artery, in most of the
operations in keeping with the objective of the Ross
procedure to maximize benefit for the longest possible
time without reoperation.
Follow-up. Patients and/or their physicians were con-
tacted for clinical outcome. Echocardiographic data were
obtained whenever available. Such echocardiographic
data were available for 96 patients, but clinical follow-up
was 95% complete spanning 345 patient-years with only
seven patients lost to follow-up. Kaplan-Meier analysis
was used to determine event-free survival curves. Data
were analyzed with SAS software (SAS, Inc., Cary, N.C.)
and plotted using SPSS software (SPSS, Inc., Chicago,
Ill.).
Table I. Previous cardiac surgery
No. of patients
(n 5 17) Type of procedure
8* Previous aortic valve repair
1 Aortic valve repair/mitral valve repair
5 Aortic valvotomy
2 Ventricular septal defect repair
1 Repair of coarctation and patent
ductus arteriosus
*One patient underwent two previous AVRs.
Table II. Concomitant procedures
No. of patients
(n 5 36) Concomitant procedure
12 Coronary artery bypass
13 Mitral valve repair
1 Mitral valve replacement
3 Septal myomectomy/resection
subaortic membrane
3 Aortic graft
1 Closure of aortoatrial fistula
1 Patent ductus arteriosus ligation
1 Ventricular septal defect closure
1 Repair septal aneurysm
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Results
Four of 145 patients (2.8%) died in the hospital,
and three others died within 6 weeks of discharge,
for a total early mortality of 4.8%. Three deaths
were in the first 15 patients and four in the subse-
quent 130 patients. Of the first three deaths, two
were caused by bleeding problems in the setting of
endocarditis and the other was the result of a
pulmonary embolus 2 weeks after discharge. Of the
last four deaths, two resulted from right ventricular
failure caused by infarction from coronary disease—
one unrecognized and one ungraftable, and the
other two were caused by arrhythmias. One patient
died at home just over 5 weeks after the operation.
The other was receiving anticoagulants for persis-
tent atrial fibrillation; a symptomatic pericardial
effusion developed, and arrest occurred 6 weeks
after the original operation with induction of anes-
thesia for drainage of that effusion. He could not be
resuscitated despite heroic efforts.
Table III lists the 14 major complications that
occurred in 12 patients (8.5%). Bleeding required
reoperation in four patients. Respiratory insuffi-
ciency affected three patients, two of whom had
transient renal failure that contributed to the pro-
longed ventilator requirement. Neither of these
required long-term dialysis. Three patients with
extensive annular calcification had persistent heart
block that required permanent pacing; one of these
patients had extensive subaortic stenosis resected as
well.
Overall patient survival is shown with the Kaplan-
Meier analysis in Fig. l with 90.5% 6 3.1% at 5 years
and 84.5% 6 14.1% at 7 years. There were four late
deaths as listed in Table IV. Two deaths were
cardiac related, one sudden and presumed to be
caused by arrhythmias and one caused by a myocar-
dial infarction. Two patients died of pulmonary
malignancies at 6 months and 21⁄2 years, respec-
tively. The two patients with lung cancer had nor-
mally functioning autograft valves, but one of the
two dying a cardiac death had moderate AR and the
other had moderately severe AR.
Endocarditis occurred in three patients—two on
the autograft (at 12 and 68 months, respectively)
and one on the pulmonary homograft (two episodes,
at 24 and 36 months in the same intravenous drug
abuser). The Kaplan-Meier freedom from endocar-
ditis is 97.2% 6 1.9% at 5 years and 92.8% 6 4.7%
at 7 years (Fig. 2).
Three patients had cerebrovascular accidents
(CVAs). One patient with systemic lupus erythem-
atosus and the anti-cardiolipin antibody syndrome
had two CVAs at 3 and 5 months after the operation
with a normally functioning valve. There was no
documented arrhythmia or clot in the heart on
echocardiography. This patient is the only one who
has been receiving anticoagulants. Two other pa-
tients had CVAs at 70 and 90 months, respectively,
again with normal echocardiograms. These two pa-
tients were both over 60 years of age at the time of
the CVA. Kaplan-Meier freedom from thromboem-
bolic events at 5 years is 99.2% 6 0.8% and at 7
years is 93.1% 6 5.5%, as shown in Fig. 3.
Six patients required additional cardiac surgery.
One patient needed mitral valve replacement 3
years after combined mitral commissurotomy and
Ross procedure. Five patients required autograft
valve replacement for regurgitation. Two of these
patients had endocarditis, and three patients had
technical failure. The technical failure in one patient
at 9 months was due to a judgment error, use of an
autograft with myxomatous degeneration and big,
floppy leaflets. The patient had significant AR from
the outset despite efforts to tether these leaflets at
the commissures. The second technical failure prob-
ably also represents imperfect initial reconstruction
with moderate AR documented on repeat catheter-
ization before discharge, ultimately leading to reop-
eration for moderately severe AR 6 years later. The
other technical failure was in a patient with inflam-
matory root disease of an ill-defined cause. Appro-
priate felt-strip support of the anulus was not used,
Table III. Operative morbidity
No. of patients
(n 5 12) Complication
4 Hemorrhage requiring reoperation
3 Heart block requiring permanant pacemaker
1 Deep sternal wound infection
2 Combined renal and respiratory failure
1 Isolated respiratory failure
1 Right ventricular failure necessitating
delayed closure of chest
Table IV. Late death (n 5 4)
Time interval since hospital
discharge (mo.) Cause of death
6.5 Cancer
24 Sudden death
32 Cancer
86 Myocardial infarction
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and significant regurgitation became apparent at 1
year. He had a valve replacement at 5 years when
class II symptoms developed. The two patients with
endocarditis underwent repeat root replacement
with cryopreserved aortic homografts. The three
technical failures had mechanical valves placed
within the previous autograft root. All did well.
Kaplan-Meier freedom from autograft reoperation
was 93.9% 6 3.1% at 5 years and 88.6% 6 6.4% at
7 years (Fig. 4).
When including death, reoperation, CVA, and
endocarditis as events, the event-free survival at 5
years is 82.7% 6 5.1% and at 7 years is 74.2% 6
7.4% (Fig. 5).
Echocardiographic information on the 38 patients
who underwent operation within the last year is only
immediate postoperative data. There are 26 echo-
cardiograms for 1- to 2-year follow-up, 16 for 2- to
5-year follow-up, and 16 for more than 5-year
follow-up. Both early and late echocardiographic
follow-up of these patients reveal a notable and
consistent absence of any significant gradients
across the autograft valve. A tiny central jet of AR is
commonly seen (Fig. 6), but more than mild AR was
seen in only nine patients in this series, seven of
whom had preoperative AR. Five of the nine pa-
tients underwent reoperations as previously de-
scribed. One died suddenly 2 years after the opera-
tion; one died of a myocardial infarction 7 years
after the operation; two others are asymptomatic,
including one who recently was delivered of a
healthy baby after an uneventful pregnancy. With
the current technique of annular support, of 45
recent studies done early after the operation, 9 were
read as “no AR,” 14 as “trace AR,” 19 as “mild
AR,” 2 as “mild to moderate AR,” and only 1
“moderate AR.”
Discussion
Our 10-year experience with the autograft root
replacement, the modified Ross procedure, clearly
confirms the original hypothesis that autograft root
replacement would result in a very low rate of
reoperation. The modified Ross procedure main-
tains the anatomy and the three-dimensional geom-
etry of the autograft. This results in a more consis-
tently competent autograft valve compared with the
intraaortic techniques of subcoronary implantation
or inclusion root. Reoperation on the autograft was
necessary in only 5 of 132 patients (3.8%) in this
series as opposed to 12% to 16% in series heavily
weighted to the subcoronary and intraaortic cylinder
Fig. 1. Kaplan-Meier patient survival.
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techniques.2, 7 Of note is the fact that all have
survived reoperation without incident. Our study
supports the study of Elkins and associates,8 who
demonstrated a significant advantage of the full root
over the cylinder and the subcoronary technique
with severe AR and reoperation as criteria. They
found an autograft reoperation rate of 3.3% (4 of
122 patients) in the root replacement group com-
pared with 6.9% (4 of 58 patients) and 11.5% (3 of
26 patients) in the groups with cylinder and subcoro-
nary implantation, respectively.
As experience with the Ross procedure has in-
creased and operative death and early technical
failure have decreased, there has been more general
acceptance of the autograft root replacement. Root
replacement is reported to be the primary technique
in 71% of the patients who undergo the Ross
procedure as recorded in the Ross Procedure Inter-
national Registry.9 An increasing number of sur-
geons8, 10-13 have reported favorably on this tech-
nique. Of particular significance is the increasingly
high percentage of full root replacements done by
Ross himself.14, 15
The modified Ross procedure does sacrifice the
advantage of closing the native aorta over the
autograft. The death of two patients from bleeding
led to a respect for the enormous potential for
bleeding from aortic suture lines, which cannot be
addressed easily or even seen at the end of this
extensive operation. The routine use of aprotinin
has helped eliminate this problem, but the strictest
attention to gentle, accurate technique is still the
most important factor.
The results of longitudinal echocardiographic fol-
low-up are somewhat limited because of the diffi-
culty of getting patients who feel so well to return
for such studies. Of nine patients who were found to
have moderate to severe AR, including the five
patients who required reoperations, seven had AR
as the original diagnosis, confirming the correlation
of this preoperative diagnosis with subsequent fail-
ure of the operation found by Elkins and associates.8
We believe that careful attention to sizing and
matching of the aorta to the autograft is particularly
important in AR. As described in the Patients and
methods section, supporting the anulus and the
distal aortic suture line with circumferential Teflon
felt strips should be a routine part of the opera-
tion when AR is the diagnosis. Potential au-
tografts with a large, myxomatous valve should
Fig. 2. Kaplan-Meier freedom from endocarditis.
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not be implanted, but rather an aortic homograft
should be used.
Although at least one third of patients have
“dilated aortic root” reported on echocardiograms
with dimensions of 3.7 to 4.2 cm, we have not seen
any progression of this root dilatation. However,
serial echocardiographic data are too limited as yet
to answer the important question of potential for
such dilatation in the freestanding autograft root in
the aortic position under systemic pressure after
many years.
We are aware that there has been a small inci-
dence of reoperation on the pulmonary homograft
in the RVOT in other series,7, 8 but so far this has
not been required in any of these patients. We
anticipate that eventual stenotic problems at the
homograft valvular level might be addressed with
balloon catheters. Similarly, pulmonary homograft
insufficiency should be a lesion that can be very
well-tolerated for many years as long as pulmonary
artery pressures are low.
The group of 11 patients with active endocardi-
tis had a high incidence of poor outcomes. Seven
of them (63.6%) had adverse events. Two were
operative deaths, and one died suddenly at 2
years. Recurrent endocarditis developed in three
patients, and two patients required reoperation.
Combined renal and respiratory failure developed
in one patient immediately after the operation.
Also of note is that the entire incidence of
postoperative endocarditis is derived from this
group of patients with active endocarditis at the
time of the original operation. Endocarditis has
not developed in any other patient after the
modified Ross procedure. Despite the desirability
of the Ross procedure for all young patients and
the success in this challenging group of infected
valves reported by others,16, 17 we advise caution
in selecting these very ill patients for such an
extensive operation. Homografts may be prefera-
ble in these patients, especially in those with
extensive annular abscesses.
This series is notably older than many other
series, with a mean age over 40 years. The absence
of pediatric patients is a reflection of the separation
of adult and pediatric programs in New York State.
As experience was gained with the procedure and
because availability of aortic homografts was very
Fig. 3. Kaplan-Meier freedom from thromboembolic events.
The Journal of Thoracic and
Cardiovascular Surgery
May 1998
1 0 9 6 Stelzer, Weinrauch, Tranbaugh
Fig. 4. Kaplan-Meier freedom from reoperation on the autograft valve.
Fig. 5. Kaplan-Meier event-free survival.
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limited (especially in larger sizes), the operation
was extended to older patients who were still
believed to have a life expectancy of 25 years or
more. Our current indications still use this bench-
mark of anticipated lifespan as a major criterion.
The presence of extensive coronary disease should
discourage the Ross procedure as a rule, but we
believe that some coronary work with arterial
grafts is justifiable. The patient with an unstable
condition or the patient with severe left ventricu-
lar dysfunction does not tolerate this extensive
operation well and should have a simpler valve
substitute. Patients with concomitant mitral dis-
ease can be considered for this operation if the
valve is repairable, especially if they are younger
than 45 years of age. The presence of chronic
atrial fibrillation would tip the scales in favor of
mechanical valves in both positions. Marfan’s
syndrome is a contraindication to the Ross proce-
dure, but a rare patient with ascending aneurysm
not amenable to a valve-sparing operation might
undergo the modified Ross procedure in combi-
nation with an ascending aortic graft. Because
more elderly patients with mechanical valves ex-
perience thromboembolic and anticoagulant-re-
lated problems, our goal is to try to perform the
Ross procedure up to the age at which a standard
tissue valve can be reasonably expected to outlive
the patient.
Conclusion
In summary, our 10-year experience with the
Ross procedure, modified by replacing the aortic
root, has confirmed the suitability and safety of
this operation for patients with aortic valve dis-
ease. It avoids anticoagulation and provides excel-
lent hemodynamics, thus allowing unrestricted
activity and lifestyle. There is a very low incidence
of technical failure with this technique, which may
be lowered even further with careful patient se-
lection and attention to root tailoring and sup-
porting elements. We conclude that the modified
Ross procedure is the preferable operation for
aortic valve replacement in younger patients but
recommend caution in patients with active endo-
carditis.
We thank Mary Lane and Ronald Elkins, MD, at the
University of Oklahoma Health Sciences Center for
providing follow-up data on the first 15 patients in this
series. We also thank Bertram I. Cohen, PhD, for
statistical and technical support.
Fig. 6. Echocardiogram illustrates minimal central AR.
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Discussion
Dr. Donald B. Doty (Salt Lake City, Utah). Dr. Stelzer
has presented a retrospective study of 145 patients who
had aortic valve and root replacement using a pulmonary
autograft, the modified Ross procedure. He operated on
all of the patients himself. The initial 15 operations were
performed in Oklahoma, and the subsequent 130 opera-
tions done in New York City. The results are excellent and
speak for themselves. There are sufficient data in fol-
low-up for Kaplan-Meier analysis at 7 or perhaps 8 years.
Only four of the patients died early, 2.8%, and significant
complications occurred in only 12 patients, 8.5%. Four
patients required reoperation for incompetence of the
pulmonary autograft in the aortic position, but two of
those were infected. There were no reoperations for the
pulmonary homograft in the pulmonary position. Stelzer
provided a significant advance in our understanding of the
Ross procedure by performing the transfer of the pulmo-
nary valve to the aortic position by using the entire
pulmonary trunk. The operation is a total, free-standing
aortic root operation and provides two important techni-
cal aspects. One, complete removal of all aortic root
components that are abnormal, and two, using the intact
pulmonary trunk in the aortic position offers the best
chance to eliminate distortion of the pulmonary valve. He
is also a proponent of external support and fixation of the
pulmonary trunk by incorporating a Teflon or pericar-
dium support collar at the proximal suture line in the left
ventricular outflow tract.
I agree completely with all of the points that Dr. Stelzer
has made and will reiterate some of them for emphasis.
Preventing failure in the Ross operation is accomplished
mainly if not entirely by meticulous attention to technical
detail. Transferring the pulmonary trunk as a complete,
free-standing root into the aortic position seems to offer
the best chance for achieving an undistorted pulmonary
valve. Size discrepancy between the aortic root and the
pulmonary trunk should be corrected by adjustment of the
size of the aortic root. The aortic root may be reduced or
enlarged, using established techniques to match it per-
fectly to the size of the pulmonary trunk. The pulmonary
trunk is flexible, distensible tissue and can be molded to
any size by constricting it in a suture line or stretching it
over an enlarged left ventricular outflow tract. Such
practice should be avoided because it may significantly
affect the apposition of the pulmonary valve cusp. A
supported root technique in which a Teflon felt or peri-
cardial ring is incorporated in the proximal suture line
appears to reduce the chance of dilation of the pulmonary
valve when subjected to systemic pressure. The support
ring also reduces bleeding. It should be recognized that
this operation requires multiple sutures and suture lines
that are all exposed but that are not readily accessible,
even on cardiopulmonary bypass.
I agree with Stelzer that the application of the Ross
procedure in patients with bacterial endocarditis that is
extended off the aortic valve cusp into adjacent tissues
with aortic root abscesses should be avoided. The Ross
operation opens more tissue planes and adds excessive
operating time for patients in whom sepsis syndrome will
persist for several hours after the operation. Aortic root
replacement with cryopreserved homograft is an estab-
lished operation that is preferred in this setting. The Ross
operation takes more time than usual aortic valve replace-
ment. In spite of the extra time of cardiac ischemia and on
cardiopulmonary bypass, the patients recover rapidly and
spend only 4 to 5 days in the hospital. Perhaps this is
related to the optimal hemodynamic performance associ-
ated with the Ross procedure. Exercise performance after
operation is especially impressive, making this operation
helpful to athletic individuals.
Now that you have enlightened us as regards the results
at 10 years after aortic valve replacement with pulmonary
autograft, would you care to speculate on what we can
anticipate between 10 and 20 years after this operation?
Dr. Stelzer. Looking to the future in answer to your
question, let me direct to two points. The autograft—I am
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convinced that if you put it in right, support it properly,
and have a competent valve, when you leave the operating
room, the chances are very good that this is going to last
for the patient’s natural lifetime. The pulmonary ho-
mograft in the RVOT then becomes the limiting factor.
There has a been a low incidence of reoperation for
stenosis of that conduit, usually at a very early time,
perhaps on an immunologic basis. I have been fortunate
that I have not had to do that yet, but it has happened in
1% or 2% of people. Because the aortic homograft in the
RVOT, in Ross’s hands, has somewhat in the range of
75% freedom from reoperation at 25 years, we have an
even better likelihood of the pulmonary homograft (hav-
ing less intrinsic calcium and thickness) lasting longer.
However, if those leaflets become stiff, calcified, stenotic,
surely they can take a balloon up there and blow it away.
Transcatheter techniques might be able to extend its life
considerably longer without reoperation; and if it becomes
incompetent at that point or gradually at that point (or
becomes so gradually), we know that people can tolerate
wide-open pulmonary insufficiency for 15 or 20 years
before they get right ventricular dilatation and perhaps
exercise-induced arrhythmias, as some of the children who
have had pulmonary valvectomy have demonstrated. This
gives me hope that we may be able to get 30 or 40 years
out of that RVOT reconstruction, which means most of
these folks will only have to have one more procedure
done on the RVOT, which is a lot easier to do than
redoing the aortic. That is my optimistic look at the future.
It has been gratifying to see people like Dr. Doty and a
number of others confirm my experience that the total
root replacement is not only a reproducible way of
providing a competent valve, but it is also teachable,
learnable, and reproducible in hands other than just mine.
I think longer follow-up of patients is necessary to confirm
these findings that there is a significant advantage of the
full root over the intraaortic techniques as first reported
by Ron Elkins last year at the Society of Thoracic Sur-
geons meeting, and this experience confirms that.
Dr. Frederic Joyce (Albany, N.Y.). Anyone who has
done a Ross operation and has seen how thin the au-
tograft is and has thought about putting it into a high-
pressure system as a free-standing aortic root is a brave
person, and you did it first. It is a brave step, but a logical
one, because you are maintaining the three-dimensional
characteristics of the pulmonary valve. But that does not
happen automatically, and I am glad that Dr. Doty
discussed a little bit about the sizing issues. Would you
comment on how you deem a pulmonary autograft satis-
factory size-wise for what you are going to be inserting it
into? In our work, we have looked a lot at the pulmonary
root sinotubular junction and used that as our major
defining dimension and related that to the aortic anulus. I
was wondering if you would comment on that. As far as
your conclusions on endocarditis, I disagree, but we will
be hearing more about that tomorrow.
Dr. Stelzer. In regard to the sizing issue, I think that 2
to 3 mm of difference between the pulmonary root and the
aorta can be made up pretty well just by incorporating a
cuff of Teflon fabric. I traditionally measure the pulmo-
nary anulus just hanging limp there with a sizer, a
standard sizer. If it is a 25, let’s say, then I will take a 27
sizer, wrap a Teflon strip around it, and cut that to size, so
I know that I have got one size bigger strip of Teflon on
the outside and that is what I incorporate. If there is more
than 5 mm difference, and usually this is bigger aorta than
pulmonary, I plicate the commissures, the trigones, espe-
cially between the left and the noncoronary sinus, and
bring it down at that point to a size that is down to the 2
to 3 mm or equal, and then incorporate the cuff on top of
that. That is the way I handle the sizes. More than a
centimeter bigger, I do not think you should do it; I think
that is just a little bit too much to make up.
About the endocarditis issue, I am looking forward to
hearing your paper, and I am glad you have had better
experience than I. I am having to report what I experi-
enced, and I must acknowledge that those two people who
died were in the first 15, that may have been a learning
curve and I was pushing the envelope a bit, and so that
may have had something to do with it. Those are the data,
and I wanted to present that.
Dr. D. Craig Miller (Stanford, Calif.). As counterpoint
to some of the enthusiasm that Dr. Doty and Dr. Joyce
and you have shared with us, and I know there are other
“Ross zealots” in the audience, some of whom do Ross
operations in patients of almost any age, let me tell you
what is going on at the Cleveland Clinic. Three weeks ago,
Dr. Cosgrove stated publicly in Boston that broad use of
the Ross procedure at the Cleveland Clinic is basically
over. Their results may be just as good as Dr. Stelzer’s, but
failures of both the autograft and the pulmonary ho-
mograft appear to have tempered his enthusiasm for this
procedure. Dr. Cosgrove currently believes that these
young patients really should not have to face this chance
of reoperation. Do you have any comments pertaining to
Dr. Cosgrove’s current posture that the Ross procedure is
not all a bed of roses?
Dr. Stelzer. I have not seen his reports and have not
talked to him lately, but I am glad he has not tried to do
this minimally invasively (laughter); but you know, I can
get these folks home quickly, some of them on postoper-
ative day 3, so I think I can justify staying with the median
sternotomy. (It has been done minimally invasively in
Berlin now by Konertz.) I do not know what the problems
are that they are encountering in Cleveland. Dr. Doty has
certainly pointed out that you must pay meticulous atten-
tion to detail; this is not an operation in which the
attending surgeon can drop in for an hour and be gone.
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